← Back to Search

Cannabinoid

THC for Psychosis Risk

Phase < 1

Waitlist Available

Led By Mohini Ranganathan, MD

Research Sponsored by Yale University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Having one relative with a confirmed psychotic disorder

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up -30 min, +240 min

Summary

This trial is testing whether people with a family history of psychosis react differently to THC than controls without a family history of psychosis.

Who is the study for?

This trial is for people who have tried cannabis at least once and are medically and mentally healthy. They must also have a relative with a confirmed psychotic disorder. It's not specified who can't join, but typically those with health issues that could interfere would be excluded.

What is being tested?

The study aims to see if having a family history of psychosis affects how the body responds to THC, an active component of cannabis. Participants will receive either very low dose THC, low dose THC, or a placebo without knowing which one they're getting.

What are the potential side effects?

While the document doesn't list specific side effects, typical reactions to THC may include altered senses or sense of time, mood changes, impaired body movement, difficulty thinking and problem-solving.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have a family member with a confirmed psychotic disorder.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ -30 min, +15 min, +80 min, +150 min, +240 min

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~-30 min, +15 min, +80 min, +150 min, +240 min

This trial's timeline: 3 weeks for screening, Varies for treatment, and -30 min, +15 min, +80 min, +150 min, +240 min for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Positive and Negative Symptom Scale for Schizophrenia (PANSS)

Secondary study objectives

Clinician Administered Dissociative Symptoms Scale (CADSS)

Hopkins Verbal Learning Test (HVLT)

Psychotomimetic States Inventory (PSI)

+1 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: No Family History of Psychosis (FHN)Experimental Treatment3 Interventions

Individuals recruited with no history of psychosis in the family. They will receive the placebo, very low dose THC, and low dose THC interventions.

Group II: Family History of Psychosis (FHP)Experimental Treatment3 Interventions

Individuals with a family member with a confirmed diagnosis of psychosis. They will receive the placebo, very low dose THC, and low dose THC interventions.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Placebo

1995

Completed Phase 3

~2670

0 / 1Eligibility criteria met